---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-014595"
form_type: "8-K"
ticker: "WINT"
cik: "0000946486"
company_name: "WINDTREE THERAPEUTICS INC /DE/"
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T02:01:31.741313+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Windtree Q1 net loss $4.1M; runway extended via $10.8M offering; EU patent granted

## Summary
- Net loss $4.1M ($4.76/sh) vs $8.1M in Q1 2022; operating loss narrowed to $4.2M from $8.3M.
- Cash $4.2M as of Mar 31; April public offering raised $10.8M net, funding through Q1 2024.
- R&D expense fell 74% to $1.4M; G&A down 23% to $2.3M; average monthly cash burn cut 58% YoY.
- European Patent Office granted SERCA2a activator patent coverage through July 2038.
- Regained Nasdaq minimum bid price compliance; publication on istaroxime cardiogenic shock dose-response.

## SEC filing metadata
- accession: 0001437749-23-014595
- form_type: 8-K
- ticker: WINT
- cik: 0000946486
- company_name: WINDTREE THERAPEUTICS INC /DE/
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946486/000143774923014595/0001437749-23-014595-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946486/000143774923014595/wint20230412_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-014595
- JSON: https://secwatch.observer/filing/0001437749-23-014595.json
- Plain text: https://secwatch.observer/filing/0001437749-23-014595.txt

## Key facts
- Earnings Releases
  WINDTREE THERAPEUTICS INC /DE/ reported quarter ended March 31, 2023 results: net income net loss of $4.1 million, EPS $4.76 per basic share.
  - Period: quarter ended March 31, 2023
  - Net income: net loss of $4.1 million
  - EPS: $4.76 per basic share
  - Result: reported results
  source text: The Company reported a net loss of $4.1 million ( $4.76 per basic share) on 0.9 million weighted-average common shares outstanding for the quarter ended March 31, 2023 , compared to a net loss of $8.1 million ( $14.36 per basic share) on 0.6 million weighted average common shares outstanding for the comparable period in 2022 .
  evidence_url: https://www.sec.gov/Archives/edgar/data/946486/000143774923014595/0001437749-23-014595-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.